Democratic-Controlled Congress Now Must Strengthen Social Security, Medicare

Published in RINewsToday on November 9, 2026

Last Tuesday’s historic 2026 midterm election was more than a routine political shift. Political pundits called it a blue wave that would reshape federal and state public policy for years. Democrats won control of both the House and Senate, flipping Republican-held Senate seats and gaining dozens of House seats. Their legislative victories extended into traditionally red states.

When the dust settled, Democrats flipped seven Republican-held Senate seats, giving them 54 seats, including two independents who caucus with Democrats, to Republicans’ 44. At press time, the results of two close Senate races, in Alaska and Mississippi, were still too close to call.

Democrats took 254 seats in the House, Republicans 162, and 19 races were still undecided as of Nov. 7. The Associated Press declared Democrats would control both chambers, though votes were still being cast in a handful of races.

Democrats also won governorships in Texas, Ohio, Iowa, Georgia, and Nevada, among other states. According to the National Conference of State Legislatures,

Democrats flipped 12 state houses, most notably in Texas, Michigan, and Minnesota, the Senate in Pennsylvania, and both chambers in Wisconsin. These victories gave Democrats control of both chambers in all four states, although some results remained unofficial.

At state houses nationwide, this shift in political leadership would give Democrats greater control over state budgets and legislation for older residents, including health care, long-term services and supports, and programs to help older adults age in place and remain independent in their communities.

Blue Wave Shifts Power on Capitol Hill

During the 120th Congress, Democrats will take control of both chambers of Congress on Jan. 3, 2027, gaining committee chairmanships, the ability to set legislative agenda priorities, hold hearings, and investigate the Trump administration.

But winning control of Congress does not guarantee legislation will easily pass.  President Donald Trump, facing a divided government during his final two years in office, has indicated he intends to use his veto power to block passage of Democratic legislation he deems damaging for the country.   

                                    ,

According to Roll Call, at the White House South Lawn on Friday morning, Oct. 23, 2026, before departing for a campaign rally in Florida, Trump was asked whether his legislative agenda would face gridlock with Democrats controlling Congress. He answered that he’d “veto, veto, veto, and then they come and they saw how we get it done, and you make a deal.”

Even if Democrats draft proposals, Senate rules, most notably the legislative filibuster, can block legislation from ever reaching the president’s desk by requiring a 60-vote supermajority to advance most bills.

Aging Groups, Advocates Share Legislative Priorities

For aging advocates, the question is whether a Democratic-controlled Congress can turn its midterm victories into legislation that improves older Americans’ financial security, health care, and quality of life.

Democratic leaders say their initial priorities include lowering household costs, addressing health program cuts, and expanding congressional oversight of the Trump administration. And aging organizations are preparing to push for legislative proposals that failed under the previously controlled Republican Congress.

Older voters played a significant role in Tuesday’s election outcome.

According to NORC’s election polling data cited by AARP, voters age 50 and older made up 60% of the midterm electorate. These voters were concerned about affordability, financial security, Social Security, and Medicare, not only for themselves but for their families.

The survey found 90% of older voters and 80% of all voters considered protecting Social Security from cuts very important. AARP says the new Congress has been entrusted with addressing challenges affecting the health and financial security of 125 million older Americans.

“Older voters showed up and made their voices heard, and now it’s Congress’s turn to deliver.

The 120th Congress must quickly address the serious challenges facing every kitchen table in America. Incoming lawmakers will shape the future of Social Security and Medicare, determine how family caregivers can receive greater support, and affect health care costs and the economic security of millions of Americans,” says AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond.

AARP has urged the new Congress to work across party lines to strengthen Social Security without cutting benefits older Americans have earned. The organization says older voters will be watching lawmakers closely.

AARP’s pre-Election Day polling identified older women as a key group of undecided voters. Similarly, NORC’s election data found older women supported Democratic candidates by nine points, while older men favored Republicans by five points.

Independent voters age 50 and older also helped determine the election outcome, with Democrats winning their support by 22 points (56% to 32%).

The economy remained a top concern among older voters. AARP’s polling found the cost of groceries (29%), health care and prescription drugs (24%), and gasoline (21%) were key factors in their voting decisions.

For Max Richtman, president and CEO of the Washington, D.C.-based National Committee to Protect Social Security and Medicare (NCPSSM), the election offers another chance to advance legislation to ensure the fiscal solvency of Social Security and Medicare and to expand these programs, which failed to gain traction in the Republican-controlled Congress.

Richtman says Social Security, Medicare, Medicaid, and prescription drug prices are closely tied to the affordability concerns that shaped the midterm elections.

The new Congress must also address Social Security’s looming financial

shortfall, warns Richtman.  According to the 2026 Social Security Trustees Report, released June 9, 2026, the Old-Age and Survivors Insurance Trust Fund is on track to run out of money in 2032. If Congress doesn’t step in before then, a sudden drop in program revenue means the government will be able to pay out only 78% of what retirees and surviving families are owed, he says.

While the sweeping Democratic victories have been described as a “Blue Tsunami,” Richtman also sees a “Silver Tsunami,” with older voters helping bring change in congressional leadership.  He believes Democratic control of both chambers offers an opportunity to strengthen Social Security and Medicare and make health care more affordable for older Americans.

Like AARP and Social Security Works, NCPSSM wants wealthier Americans to contribute more to Social Security and Medicare. By rewriting the Social Security payroll tax rules for the wealthiest Americans, these bills would ensure the wealthy pay their fair share. The group supports using additional revenue to strengthen the programs’ finances and expand benefits.

Richtman says that if reintroduced, NCPSSM would support the following three major bills to strengthen Social Security and Medicare.

The Social Security 2100 Act (H.R. 9519/S. 5042), introduced by Rep. John Larson (D-CT) and Sen. Richard Blumenthal (D-CT), would strengthen Social Security’s finances and improve benefits. The legislation would remove the existing cap on earnings subject to Social Security payroll taxes and require wealthy Americans to pay additional taxes on investment income exceeding $400,000. It would also use the Consumer Price Index for the Elderly (CPI-E) to calculate annual cost-of-living adjustments and increase minimum benefits for low-income workers.

The Social Security Expansion Act (S. 770/H.R. 1700), introduced by Sen. Bernie Sanders (I-VT) and Rep. Val Hoyle (D-OR), would expand Social Security benefits while strengthening the program’s long-term finances. The legislation would require Americans earning more than $250,000 to pay additional Social Security taxes and increase taxes on certain investment income of higher-income individuals. It would also use the CPI-E to calculate annual cost-of-living adjustments, improve minimum benefits for low-wage workers and restore student benefits through age 22 for eligible children of deceased, disabled or retired workers.

Finally, the Medicare and Social Security Fair Share Act (S. 1690/H.R. 3271), introduced by Sen. Sheldon Whitehouse (D-RI) and Rep. Brendan Boyle (D-PA), would strengthen the finances of both programs by requiring wealthier Americans to contribute more in taxes. The legislation would apply Social Security payroll taxes to earnings above $400,000, require high-income individuals to contribute more to Medicare, and close loopholes that allow some wealthy business owners to avoid Medicare taxes. It would also expand taxes on investment income of higher-income Americans.

During the new Congress, Richtman says NCPSSM will push for Medicare reforms, including adding dental, vision, and hearing benefits; limiting out-of-pocket costs; expanding prescription drug price negotiations; and addressing overpayments and inappropriate care denials in Medicare Advantage plans.

Other NCPSSM priorities include extending enhanced Affordable Care Act premium tax credits and reversing recent cuts to Medicaid and Supplemental Nutrition Assistance Program benefits.

Nancy Altman, president of Social Security Works and chair of the Strengthen Social Security coalition, also sees an opportunity for Democrats to act. “Democrats just got a huge mandate from voters after running campaigns that focused on strengthening Social Security by making the wealthy pay their fair share, along with making health care affordable,” says Altman.

She believes Democrats should make passage of the Social Security Expansion Act a top priority and send the legislation to President Trump’s desk. The proposal would increase Social Security benefits and strengthen the program’s long-term financing by requiring higher-income Americans to contribute more, including taxes on certain investment income. Altman points to wealthy Americans, including Elon Musk, as examples of individuals who could contribute more under the proposal.

According to the Alliance for Retired Americans, seven Democratic Senate candidates who won Republican-held seats in Kansas, Texas, North Carolina, Maine, South Carolina, Iowa, and Ohio campaigned to raise the amount of income subject to Social Security payroll taxes. Their election could support proposals backed by NCPSSM and Social Security Works to increase contributions from higher earners and help prevent future benefit cuts.

Altman warns that if Trump vetoes legislation to strengthen Social Security by requiring wealthier Americans to pay more, Republicans could face political consequences in the 2028 election. She also wants Congress to reconsider Medicare for All legislation. “Our already frayed health care system is coming apart at the seams due to Republican cuts to Medicaid and the ACA. Now is the time to improve Medicare and expand it to cover everyone in America,” says Altman.

A Final Note…

Robert Weiner, a former Clinton White House spokesman who served as chief of staff of the House Select Committee on Aging under the late Rep. Claude Pepper (D-FL), says the new Congress must protect Social Security and stop calling proposed benefit cuts “reform.”

“This rhetoric is an immediate third rail and political suicide,” says Weiner. He believes raising the amount of earnings subject to Social Security payroll taxes could help address the program’s projected funding shortfall.

“Protecting Social Security is crucial to retaining voter support on both sides. One partial solution is straightforward and has been proposed by members of both parties,” he says.

Weiner supports raising the payroll tax cap to help prevent future benefit reductions. He cited a projected 22% benefit reduction by 2034. However, the 2026 Social Security Trustees Report projects the retirement and survivors trust fund will have enough income to pay 78% of scheduled benefits in 2032, while the combined retirement, survivors, and disability trust funds would have enough income to pay 83% of scheduled benefits in 2034.

Weiner also wants the new Congress to reestablish the House Select Committee on Aging, giving lawmakers a forum to focus on issues affecting older Americans. “The new Congress should also recreate a House Aging Committee to allow focus on seniors’ issues,” says Weiner.

He also calls for restoring Affordable Care Act premium tax subsidies and reversing Medicaid cuts, warning millions of Americans, including older adults, could lose their health insurance because they cannot afford the premiums.

“Studies are clear that people die in large proportions if they do not have health insurance,” he says.

Weiner also questions claims that the United States has the world’s best health care system. “The USA mortality rates are among the worst in the civilized world. Let’s not pretend that our health system is the best,” he says.

With the midterms behind us, Weiner shares his thoughts in a USA Today op-ed on how congressional Democrats, Republicans, and President Trump can avoid legislative gridlock.  He writes that sharing a positive legacy will ensure bipartisan legislative achievements.  Democrats can win midterms and still avoid Trump gridlock | Opinion

Medicare Enrolled will see Lower Costs on Select Drugs in 2026

Published in Blackstone Valley Call & Times on December 2, 2025

With Medicare Open Enrollment ending next week, the Centers for Medicare & Medicaid Services (CMS) has announced that last year’s Medicare negotiations produced a net savings of 44%—about $12 billion—on 15 widely used prescription drugs that treat cancer and other serious chronic conditions.

The new Maximum Fair Prices (MFPs) for these 15 drugs will take effect on January 1, 2027. Combined with the 10 drugs already negotiated—whose MFPs take effect January 1, 2026—a total of 25 drugs will have negotiated lower prices. These medications, used to treat conditions such as cancer, diabetes, asthma, and cardiovascular and neurological disorders, represent some of the highest Medicare Part D spending.

The Beginning of Drug Price Negotiations

Three years ago, after President Biden signed the Inflation Reduction Act (IRA) in August 2022, CMS began developing the process for Medicare’s first-ever drug price negotiations. On March 15, 2023, the federal agency issued its initial program guidance and received more than 7,500 public comments from consumer groups, patient advocates, drug manufacturers, and pharmacies. Revised guidance followed on June 30, 2023.

On August 29, 2023, CMS released the first list of 10 high-cost drugs selected for negotiation—marking the first time in Medicare’s history that it could negotiate directly with pharmaceutical companies.

Pharmaceutical industry groups and several companies attempted to block the law in court. In response, 70 organizations and 150,000 petition signers urged Merck, Bristol Myers Squibb, Janssen Pharmaceuticals, Astellas Pharma US, the Pharmaceutical Research and Manufacturers of America (PhRMA), and the U.S. Chamber of Commerce to drop their lawsuits. Multiple organizations also filed amicus briefs supporting the law.

Three years in process, and with courts ultimately allowing the program to proceed, that first round of 10 drugs with negotiated prices will take effect in 2026.

CMS Drug Negotiations Added 15 Drugs

On January 17th, CMS announced it had selected 15 additional drugs for the second cycle of negotiations under Medicare Part D and on November 25th, it was announced that agreements had been reached on all of them. These medications are among the most costly and most commonly used by Medicare beneficiaries, treating conditions such as cancer, diabetes, and asthma. The new round of negotiations is expected to save Medicare billions and strengthen the program’s long-term sustainability.

“This year’s results stand in stark contrast to last year’s,” said CMS Administrator Mehmet Oz, MD, in announcing the second cycle of negotiations.  “Using the same process with a bolder direction, we have achieved substantially better outcomes for taxpayers and seniors in the Medicare Part D program — not the modest or even counterproductive ‘deals’ we saw before.”

“Whether through the Inflation Reduction Act or President Trump’s Most Favored Nation policy, this is what serious, fair, and disciplined negotiation looks like,” adds CMS Deputy Administrator and Medicare Director Chris Klomp. “I’m deeply proud of our team, who execute exceptionally well to bring affordability to the country in everything we do.”

Between January 1 and December 31, 2024, approximately 5.3 million Medicare Part D enrollees used one or more of these 15 drugs. Total gross Part D spending for them was $42.5 billion, representing about 15% of all Part D drug costs.

Anthony Wright, executive director of Families USA, praised the newly released negotiated prices, stating that they show what is possible when “policymakers put patients before corporate profits.” Wright emphasized that these reductions build on the work of establishing the Drug Price Negotiation Program, which aims to provide financial relief to older adults and people with disabilities.

Wright noted that the first and second rounds of negotiated drugs together account for about one-third of Medicare Part D spending, with price reductions ranging from 38% to 85%. In 2027, beneficiaries using these drugs are projected to save $685 million in out-of-pocket costs. He added that the savings support both individual beneficiaries and the long-term sustainability of the Medicare program.

Despite pharmaceutical companies’ continued attempts to limit the program—through lawsuits and legislative provisions such as those in H.R. 1—Wright said the negotiation program remains “the most effective tool currently available to lower drug prices.”

“The Medicare Negotiation Program changed the trajectory of drug pricing in the United States, helping to reduce Big Pharma’s monopoly pricing power, which dictated prices to Americans on Medicare for two decades,” said Merith Basey, executive director of Patients for Affordable Drugs in a statement. “This second round of negotiations — now under President Trump — marks another major milestone, delivering continued savings for patients and taxpayers,” he said.

“The lower negotiated prices are more than numbers on a page. For patients who’ve been forced to work multiple jobs, cut pills in half, or choose between filling a prescription and buying groceries, these lower prices will bring long-overdue relief, flexibility, and stability,” added Basey.

“The requirement that Medicare negotiate lower prices for prescription drugs continues to pay dividends for older Americans and taxpayers,” adds Richard Fiesta, executive director of the Alliance for Retired Americans. “The announcement of lower drug prices for 15 high-priced drugs is a win for more than 5 million seniors who take these drugs to treat asthma, diabetes, lung disease and other serious conditions, and will soon pay less for their medications,” he says.

“The 4.4 million members of the Alliance are pleased that the Trump Administration has followed the law, negotiated these prices, and defended this law in court,” Fiesta says, calling on Congress to increase the number of drugs subject to price negotiations.

While the White House along with aging groups praise the impact of IRA’s Medicare drug negotiation provisions, the Pharmaceutical Research and Manufacturers of America (PhRMA) issued a statement calling it “flawed.”

“Whether it is the IRA or MFN, government price setting for medicines is the wrong policy for America. Price setting does nothing to rein in PBMs who decide which medicines are covered and what patients pay. In fact, many patients are facing additional coverage barriers and paying more out-of-pocket for medicines because of the IRA, warns Alex Schriver, Senior Vice President of Public Affairs.

“These flawed policies also threaten future medical innovation by siphoning $300 billion from biopharmaceutical research, undermining the American economy and our ability to compete globally,” states Schriver, noting that PhRMA members are stepping up to make medicines more affordable by enabling direct purchase at lower prices and investing in U.S. manufacturing and infrastructure.

Lower Drug Cost Legislation Introduced

Congressman John B. Larson (D-CT), a senior member of the House Ways and Means Committee, praised the latest CMS announcement, estimating that both negotiation rounds will save older Americans more than $2 billion per year in out-of-pocket costs. Larson noted that families and seniors continue to struggle with rising prices, especially for prescription drugs.  The lawmaker pushed to enable Medicare to negotiate drug prices to lower drug costs by the enactment of IRA.

Last week, House Democrats introduced the Lower Drug Costs for American Families Act, aimed at closing loopholes in H.R. 1 and further reducing prescription drug prices. The bill (H.R. 6166), introduced November 20 by Ranking Members Frank Pallone Jr. (Energy and Commerce), Richard Neal (Ways and Means), and Bobby Scott (Education and Workforce), has been referred to all three committees.

Key provisions of the bill would:

  • Extend Medicare’s price negotiation authority to all Americans with private insurance—covering more than 164 million people with employer-sponsored plans and over 24 million enrolled in Affordable Care Act plans
  • Apply inflation-based rebate protections to private insurance markets, potentially saving $40 billion over 10 years
  • Increase the number of negotiated drugs from 20 to 50 per year
  • Extend the $2,000 annual out-of-pocket prescription drug cap to privately insured patients
  • Cap insulin costs at $35 per month for those with private insurance
  • Close the orphan-drug loophole that allows companies to avoid negotiation
  • Require consideration of international drug prices to ensure Americans do not pay three to five times more than patients in other countries

Continue the Momentum

According to CMS, the agency will announce the specifics on 15 drugs for the third round of Medicare price negotiations by February 1, 2026. This new round will include drugs paid under Medicare Part B for the first time and will begin with negotiated prices effective January 1, 2028. CMS has already released final guidance for the program and will also use this process to select drugs for renegotiation in previous cycles. IRA also establishes an ongoing process where more drugs will be selected for negotiation in subsequent years.

A Dec. 2024 AARP survey found that almost 3 in 5 adults age 50 and older expressed concern about their ability to afford prescriptions over the near future.  Respondents included both Medicare beneficiaries and younger persons. About 96 percent of the respondents call on the government to do more to lower pharmaceutical prices.

AARP noted that this survey was taken right before a new $2,000 cap on out-of-pocket drug expenses took effect in 2025.

With the announcement of lower drug costs that result from Medicare’s round 2 drug negotiations, there is an  opportunity to build on this momentum for real change. Lawmakers can legislate to put the public’s health above profit by giving consumers more power to negotiate, making competition stronger, and keeping patients from having to pay too much out of pocket.

It is now time for Congress to act.